INVO Fertility (NASDAQ:IVF) Issues Earnings Results

INVO Fertility (NASDAQ:IVF) issued its quarterly earnings results on Monday. The company reported ($3.38) EPS for the quarter, FiscalAI reports. The business had revenue of $2.02 million for the quarter. INVO Fertility had a negative return on equity of 343.57% and a negative net margin of 183.75%.

INVO Fertility Stock Down 1.4%

Shares of NASDAQ IVF opened at $1.37 on Wednesday. INVO Fertility has a 52-week low of $1.26 and a 52-week high of $183.60. The company has a debt-to-equity ratio of 0.15, a quick ratio of 0.25 and a current ratio of 0.27. The stock has a market cap of $2.45 million, a P/E ratio of -0.00 and a beta of 2.33. The firm has a 50 day moving average price of $1.73 and a 200 day moving average price of $3.76.

Wall Street Analysts Forecast Growth

IVF has been the topic of a number of recent research reports. Wall Street Zen raised shares of INVO Fertility from a “sell” rating to a “hold” rating in a research note on Saturday, March 7th. Weiss Ratings upgraded INVO Fertility from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, INVO Fertility currently has an average rating of “Moderate Buy” and an average price target of $20.00.

Hedge Funds Weigh In On INVO Fertility

A hedge fund recently bought a new position in INVO Fertility stock. Armistice Capital LLC purchased a new stake in INVO Fertility, Inc (NASDAQ:IVF) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 207,644 shares of the company’s stock, valued at approximately $156,000. Armistice Capital LLC owned 8.69% of INVO Fertility as of its most recent SEC filing. 12.02% of the stock is currently owned by hedge funds and other institutional investors.

About INVO Fertility

INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.